a nanorobot

Abstract

The invention relates to a nanorobot, comprising: a loading part, used for loading a labeling reagent; a power part, used for generating power according to environmental conditions, and the direction of the power is a direction away from the loading part; connecting parts, respectively connected to the The load component and the power component are connected so that the power component seals the load component and is disconnected when the power is greater than a preset value. Through the technical solution of the embodiment of the present invention, since the power part can generate power according to the environmental conditions, the user can set the environmental conditions according to the needs, so that the power generated by the power part is greater than the preset value when needed, so that the connecting part is broken, and the power The part is separated from the loading part, and the labeling reagent in the loading part flows out to mark the diseased cells. It allows doctors to accurately determine the distribution of diseased cells in the patient's body in order to determine the condition and treat the disease.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to a nanorobot. Background technique [0002] Most of the existing anticancer drugs enter the human body through oral administration, infusion, etc. While inhibiting and killing cancer cells, they also have the same effect on normal cells in the human body, seriously affecting the health of patients. For example, bleomycin, mitomycin and other drugs are currently commonly used anticancer drugs, but their side effects are obvious, and they are likely to cause various symptoms such as anemia and vomiting. Therefore, direct use is not conducive to the health of patients and is not conducive to Cancer diagnosis and treatment. [0003] In order to effectively treat cancer, tumor-specific markers such as alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and neuron-specific enolase (NSE) are used in the prior art to mark cancer cells, but the above-mentioned markers All of these ...

AI Technical Summary

Problems solved by technology

[0002] Most of the existing anticancer drugs enter the human body through oral administration, infusion, etc. While inhibiting and killing cancer cells, they also have the same effect on normal cells in the human body, seriously affecting the health of patients

For example, bleomycin, mitomycin and other drugs are currently commonly used anticancer drugs, but their side effects are obvious, and they are likely to cause various symptoms such as anemia and vomiting. Therefore, direct use is not conducive to the health of patients and is not conducive to Cancer Treatment

[0003] In order to effectively treat cancer, tumor-specific markers such as alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and neuron-specific enolase (NSE) are used in the prior art to mark cancer cells, but the above-mentioned markers All of them lack versatility, can only reflect a few or one kind of malignant tumors, have no diagnostic value for other malignant tumors, and the marking process is uncontrollable, so it is difficult to carry out targeted marking according to user needs

Images